help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Clark, J. H.
Right arrow Articles by Peck, E. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Clark, J. H.
Right arrow Articles by Peck, E. J., Jr

Endocrinology, Vol 100, 91-96, Copyright © 1977 by Endocrine Society


ARTICLES

Nuclear binding and retention of the receptor estrogen complex: relation to the agonistic and antagonistic properties of estriol

JH Clark, Z Paszko and EJ Peck Jr

The relationship between nuclear retention or residency or receptor estrogen complexes and the agonistic and antagonistic properties of estriol was examined. Cytoplasmic estrogen receptor (Rc) and uterine weight were measured 24 and 48 h after treatment with estradiol (E2), estriol (E3), or or both hormones (E2 and E3). Levels of Rc were elevated in all groups at either time. Since levels of Rc were above control in each case, Rc does not appear to be the limiting factor in the antagonistic effect of estriol. Therefore, the effect of these steroids on translocation and retention of nuclear receptor estrogen complexes (RnE) was examined. Rats were injectd as above and RnE measured by 3[H] estradiol exchange 1, 3, and 6 h after injection. All treatments cause equal translocation of receptor of the nuclear compartment. However, by 6 h the quantity of Rn present in E2 treated animals was significantly above controls while that in E2 + E3 animals was intermediate. E3 alone failed to cause significant nuclear retention of Rn. These patterns of retention correlate with the weight and cytoplasmic receptor responses above and suggest that the short nuclear residency time of RnE3 complexes relates to the antagonism of E3. To test this, these estrogens were administered via paraffin pellets to maintain blood levels of each hormone. Levels of Rn were elevated 24 and 48 h after implant with no significant differences between treatment groups. Likewise, there were no differences in the growth response. Uterine weights were highly stimulated in all three cases (300% above control). These results indicate that E3 acts as an estrogen antagonist when injected as a bolus because of the short nuclear retention time of RnE3 complexes. However, when E3 is present continuously and RnE3 is elevated and maintained, E3 is a potent estrogen without antagonistic properties.


This article has been cited by other articles:


Home page
Toxicol SciHome page
D. R. Plowchalk and J. Teeguarden
Development of a Physiologically Based Pharmacokinetic Model for Estradiol in Rats and Humans: A Biologically Motivated Quantitative Framework for Evaluating Responses to Estradiol and Other Endocrine-Active Compounds
Toxicol. Sci., September 1, 2002; 69(1): 60 - 78.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
G. E. Hale, C. L. Hughes, and J. M. Cline
Endometrial Cancer: Hormonal Factors, the Perimenopausal ""Window of Risk,"" and Isoflavones
J. Clin. Endocrinol. Metab., January 1, 2002; 87(1): 3 - 15.
[Abstract] [Full Text] [PDF]


Home page
Mol Hum ReprodHome page
W.-L. Di, G. C.L. Lachelin, H.H.G. McGarrigle, N.S.B. Thomas, and D.L. Becker
Oestriol and oestradiol increase cell to cell communication and connexin43 protein expression in human myometrium
Mol. Hum. Reprod., July 1, 2001; 7(7): 671 - 679.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
G. Ursin, S. London, F. Z. Stanczyk, E. Gentzschein, A. Paganini-Hill, R. K. Ross, and M. C. Pike
Urinary 2-Hydroxyestrone/16{alpha}-Hydroxyestrone Ratio and Risk of Breast Cancer in Postmenopausal Women
J Natl Cancer Inst, June 16, 1999; 91(12): 1067 - 1072.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
M. Melamed, E. Castaño, A. C. Notides, and S. Sasson
Molecular and Kinetic Basis for the Mixed Agonist/Antagonist Activity of Estriol
Mol. Endocrinol., November 1, 1997; 11(12): 1868 - 1878.
[Abstract] [Full Text]


Home page
ScienceHome page
J Fishman and D Tulchinsky
Suppression of prolactin secretion in normal young women by 2-hydroxyestrone
Science, October 3, 1980; 210(4465): 73 - 74.
[Abstract] [PDF]


Home page
ScienceHome page
J Fishman, D. Fukushima, J O'Connor, and H. Lynch
Low urinary estrogen glucuronides in women at risk for familial breast cancer
Science, June 8, 1979; 204(4397): 1089 - 1091.
[Abstract] [PDF]


Home page
ScienceHome page
S McCormack and J. Clark
Clomid administration to pregnant rats causes abnormalities of the reproductive tract in offspring and mothers
Science, May 11, 1979; 204(4393): 629 - 631.
[Abstract] [PDF]


Home page
ScienceHome page
J. Clark and S McCormack
Clomid or nafoxidine administered to neonatal rats causes reproductive tract abnormalities
Science, July 8, 1977; 197(4299): 164 - 165.
[Abstract] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
M. T. Preisler-Mashek, N. Solodin, B. L. Stark, M. K. Tyriver, and E. T. Alarid
Ligand-specific regulation of proteasome-mediated proteolysis of estrogen receptor-alpha
Am J Physiol Endocrinol Metab, April 1, 2002; 282(4): E891 - E898.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1977 by The Endocrine Society